financetom
Business
financetom
/
Business
/
Denim Trend Boosts Abercrombie As Outlook, Stock Climb
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Denim Trend Boosts Abercrombie As Outlook, Stock Climb
Aug 28, 2025 12:14 PM

Abercrombie & Fitch Company ( ANF ) shares are trading higher on Thursday.

Yesterday, the company reported second-quarter adjusted earnings per share of $2.32, beating the analyst consensus estimate of $2.30.

Quarterly sales of $1.209 billion (+7% year over year) outpaced the Street view of $1.195 billion.

ANF stock is gaining positive traction. Check out the latest moves here.

The company raised its fiscal year 2025 GAAP earnings per share guidance from a prior range of $9.50 to $10.50 to a new range of $10 to $10.50, compared to the previous estimate of $10.28.

Also Read: Dick’s Sporting Goods Q2 Sales Jump 5% On Higher Average Ticket

It also lifted its fiscal year 2025 sales guidance from a range of $5.100 billion to $5.250 billion to a new range of $5.200 billion to $5.290 billion, versus the $5.205 billion estimate.

Telsey Advisory Group analyst Dana Telsey reiterated the Outperform rating and gave the stock a price target of $125.

Telsey views the second-quarter topline beat, above-consensus third-quarter guide and higher full-year outlook as evidence of durable brand momentum, led by stronger teen engagement at Hollister.

The analyst notes that inventory exited the second quarter in a cleaner position, with management being “ready to chase” into the back half and leaning into what’s working.

Following a tougher prior quarter, early third-quarter reads are encouraging across boho, western and denim.

Importantly, denim strength is occasion-driven rather than tied to a single silhouette, with traction in low-rise, baggy, wide-leg and bootcut fits, Telsey writes.

The analyst also highlights solid results from the broader distribution of Abercrombie Kids at at Bloomingdale’s, DICK’S Sporting Goods, Inc. , Macy’s, Inc. and Nordstrom. By contrast, there are no plans to widen distribution for Abercrombie or Hollister given their already larger store footprints relative to Kids.

The combination of healthier inventory and clearer category winners positions the company to respond quickly to demand.

Overall, Telsey frames the outlook as supportive of sustained relevance and improved flexibility into the second half.

The analyst now models FY25 consolidated comp growth of 4.7%, up from prior estimation of 3.1%. Telsey added that this implies total revenue growth of 7%, raised from 5.9%.On earnings, the analyst now expects FY25 EPS of $9.91, lowered from $10.30 on incremental tariff headwinds.

ANF Price Action: ANF shares are trading higher by 2.30% to $97.55 at publication on Thursday.

Read Next:

Wall Street’s Most Accurate Analysts Spotlight On 3 Tech & Telecom Stocks Delivering High-Dividend Yields

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
Nov 4, 2025
Overview * InspireMD ( NSPR ) Q3 revenue grows 39% yr/yr, beating analyst expectations * Net income for Q3 beats analyst estimates despite larger net loss * Company attributes revenue growth to U.S. launch and international market penetration Outlook * InspireMD ( NSPR ) highlights strong demand for its CGuard Prime globally * Company emphasizes strategic focus on U.S. commercial...
Sotera Health beats Q3 estimates, raises FY profit guidance
Sotera Health beats Q3 estimates, raises FY profit guidance
Nov 4, 2025
Overview * Sotera Health ( SHC ) Q3 revenue rose 9.1% to $311 mln, beating analyst expectations * Adjusted EPS for Q3 increased to $0.26, surpassing analyst estimates * Adjusted EBITDA for Q3 rose 12.2% to $164 mln, exceeding expectations Outlook * Sotera Health ( SHC ) raises 2025 Adjusted EBITDA growth range to 6.75%-7.75% * Company reaffirms 2025 net...
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Nov 4, 2025
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc ( RPRX ) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s...
Neuronetics Q3 revenue misses estimates
Neuronetics Q3 revenue misses estimates
Nov 4, 2025
Overview * Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations * U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis * CEO Keith J. Sullivan to retire in June 2026, search for successor underway Outlook * Company expects Q4 2025 revenue between $40 mln and $43 mln * Neuronetics ( STIM ) revises 2025...
Copyright 2023-2026 - www.financetom.com All Rights Reserved